Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Phase 1

Completed

• Conditions: Lymphoid Malignancy (Lymphoma and CLL); Leukemia; Lymphoma; Solid Tumor Malignancy
• Interventions: Drug: SNX-5422 Mesylate Hsp90 inhibitor

• Registration Number: NCT00647764
• Lead Sponsor: Esanex Inc.

Brief Summary

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-03
• Study First Submitted: 2008-03-27
• Study First Submitted QC: 2008-03-31
• Study First Posted: 2008-04-01
• Primary Completion: 2010-09
• Study Completion: 2010-09
• Status Verified: 2012-05
• Last Update Submitted: 2012-05-15
• Last Update Posted: 2012-05-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

• Solid tumors or lymphoid malignancies refractory to standard therapy
• measurable disease
• recovery to Grade < 1 toxicity due to prior adverse event or chemotherapy
• no chemotherapy within 4 weeks of entering study
• Age > 18 years
• Karnofsy >= 60%
• Life expectancy > 3 months
• normal or adequate organ and marrow function

Exclusion Criteria

• receiving other investigational agents
• brain metastases
• uncontrolled medical illness
• HIV+ receiving combination antiretroviral therapy
• significant GI disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single Arm	SNX-5422 Mesylate Hsp90 inhibitor	-

Primary Outcome Measures

Name	Time	Method
MTD, safety and toxicity	continuous

Secondary Outcome Measures

Name	Time	Method
pharmacokinetic profile of SNX-5422	first cycle
tumor response measured by X-rays or scans	after every 2 cycles

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇺🇸 Bethesda, Maryland, United States